Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease

被引:23
|
作者
Facchinetti, Fabrizio [1 ]
Civelli, Maurizio [1 ]
Singh, Dave [2 ]
Papi, Alberto [3 ]
Emirova, Aida [4 ]
Govoni, Mirco [4 ]
机构
[1] Corp Preclin R&D, Parma, Italy
[2] Manchester Univ NHS Fdn Hosp Trust, Med Evaluat Unit, Manchester, Lancs, England
[3] Univ Ferrara, Dept Translat Med, Resp Med, Ferrara, Italy
[4] Global Clin Dev, Parma, Italy
关键词
phosphodiesterase 4 inhibitors (PDE4i); asthma; COPD-chronic obstructive pulmonary disease; inhaled administration; inflammation; SURFACTANT PROTEIN-D; METERED-DOSE INHALER; PHOSPHODIESTERASE-4; INHIBITOR; EOSINOPHILIC INFLAMMATION; PRECLINICAL PHARMACOLOGY; TRIPLE THERAPY; CYCLIC-AMP; ROFLUMILAST; COPD; CHF6001;
D O I
10.3389/fphar.2021.740803
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chronic respiratory diseases are the third leading cause of death, behind cardiovascular diseases and cancer, affecting approximately 550 million of people all over the world. Most of the chronic respiratory diseases are attributable to asthma and chronic obstructive pulmonary disease (COPD) with this latter being the major cause of deaths. Despite differences in etiology and symptoms, a common feature of asthma and COPD is an underlying degree of airways inflammation. The nature and severity of this inflammation might differ between and within different respiratory conditions and pharmacological anti-inflammatory treatments are unlikely to be effective in all patients. A precision medicine approach is needed to selectively target patients to increase the chance of therapeutic success. Inhibitors of the phosphodiesterase 4 (PDE4) enzyme like the oral PDE4 inhibitor roflumilast have shown a potential to reduce inflammatory-mediated processes and the frequency of exacerbations in certain groups of COPD patients with a chronic bronchitis phenotype. However, roflumilast use is dampened by class related side effects as nausea, diarrhea, weight loss and abdominal pain, resulting in both substantial treatment discontinuation in clinical practice and withdrawal from clinical trials. This has prompted the search for PDE4 inhibitors to be given by inhalation to reduce the systemic exposure (and thus optimize the systemic safety) and maximize the therapeutic effect in the lung. Tanimilast (international non-proprietary name of CHF6001) is a novel highly potent and selective inhaled PDE4 inhibitor with proven anti-inflammatory properties in various inflammatory cells, including leukocytes derived from asthma and COPD patients, as well as in experimental rodent models of pulmonary inflammation. Inhaled tanimilast has reached phase III clinical development by showing promising pharmacodynamic results associated with a good tolerability and safety profile, with no evidence of PDE4 inhibitors class-related side effects. In this review we will discuss the main outcomes of preclinical and clinical studies conducted during tanimilast development, with particular emphasis on the characterization of the pharmacodynamic profile that led to the identification of target populations with increased therapeutic potential in inflammatory respiratory diseases.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] The role of nebulized inhaled corticosteroid therapy in adult patients with asthma and chronic obstructive pulmonary disease
    Philip Marcus
    Advances in Therapy, 2005, 22 : 407 - 418
  • [42] The role of nebulized inhaled corticosteroid therapy in adult patients with asthma and chronic obstructive pulmonary disease
    Marcus, P
    ADVANCES IN THERAPY, 2005, 22 (04) : 407 - 418
  • [43] The preclinical pharmacology of roflumilast - A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease
    Hatzelmann, Armin
    Morcillo, Esteban J.
    Lungarella, Giuseppe
    Adnot, Serge
    Sanjar, Shahin
    Beume, Rolf
    Schudt, Christian
    Tenor, Hermann
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2010, 23 (04) : 235 - 256
  • [44] Bronchoscopic treatment of asthma and chronic obstructive pulmonary disease
    Schuhmann, Maren
    PNEUMOLOGE, 2020, 17 (01): : 22 - 27
  • [45] Efficacious Inhaled PDE4 Inhibitors with Low Emetic Potential and Long Duration of Action for the Treatment of COPD
    De Savi, Chris
    Cox, Rhona J.
    Warner, Daniel J.
    Cook, Anthony R.
    Dickinson, Mark R.
    McDonough, Amy
    Morrill, Louis C.
    Parker, Beth
    Andrews, Glen
    Young, Simon S.
    Gilmour, Peter S.
    Riley, Rob
    Dearman, Matthew S.
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (11) : 4661 - 4676
  • [46] How and when to use inhaled corticosteroids in chronic obstructive pulmonary disease?
    Anton, Esther
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2013, 7 (02) : 25 - 32
  • [47] Responsiveness to inhaled corticosteroid treatment in patients with asthma-chronic obstructive pulmonary disease overlap syndrome
    Lim, Hyo Seok
    Choi, Sun Mi
    Lee, Jinwoo
    Park, Yong Sik
    Lee, Sang-Min
    Yim, Jae-Joon
    Yoo, Chul-Gyu
    Kim, Young Whan
    Han, Sung Koo
    Lee, Chang-Hoon
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2014, 113 (06) : 652 - 657
  • [48] Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD)
    Grootendorst, DC
    Gauw, SA
    Benschop, N
    Sterk, PJ
    Hiemstra, PS
    Rabe, KF
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2003, 16 (06) : 341 - 347
  • [49] Effects of inhaled budesonide on insulin sensitivity in nondiabetic patients with asthma and chronic obstructive pulmonary disease
    Canis, Recep
    Dernirkok, Sevtap Sipahi
    Osar, Zeynep
    Balci, Huriye
    Can, Guenay
    ADVANCES IN THERAPY, 2007, 24 (03) : 560 - 570
  • [50] Overlap of asthma and chronic obstructive pulmonary disease
    Guerra, S
    CURRENT OPINION IN PULMONARY MEDICINE, 2005, 11 (01) : 7 - 13